Cambridge biotech XTuit Pharmaceuticals (Opens in a new window) just raised a $22 million Series A, according to a news release (Opens in a new window). The startup’s therapeutics target the disease-inducing microenvironment of cancers and fibrotic disease.
The funding will advance XTuit’s work in cancer immunotherapy and cirrhosis – with microenvironment-activated drugs that reverse disease progression, it said. It’s also building out a tissue-based biomarker platform to gauge efficacy.
The scientific basis of the company comes from a trio of lauded researchers, founded in 2011 by Harvard professor Rakesh Jain (Opens in a new window), MIT chemical engineering professor Bob Langer (Opens in a new window) and Salk Institute professor Ronald Evans (Opens in a new window) (who, notably, is in the midst of launching another stealth startup – Metacrine (Opens in a new window)).
(Opens in a new window)
Your Guide to the Best Vein Clinics in Orlando (Opens in a new window)
Your varicose or spider veins may indicate an underlying problem, so finding the right vein specialist is crucial. Discover the best vein clinics in Orlando.
This is XTuit’s official emergence from stealth mode, but MedCity News (Opens in a new window) was the first to report on XTuit’s activity back in December.
Funding comes from New Enterprise Associates, Polaris Partners, CTI Life Sciences, Arcus Ventures and Omega Funds.